Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab Extension Study in Severe Allergic Asthma
NCT00482248Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2003
- Primary completion
- Jun 2006
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of omalizumab in allergic asthma, sponsored by Novartis. Started Jun 2003; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00482248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482248.